Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash from Financing Activities (2016 - 2025)

Syndax Pharmaceuticals has reported Cash from Financing Activities over the past 11 years, most recently at $5.9 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $5.9 million for Q4 2025, down 98.3% from a year ago — trailing twelve months through Dec 2025 was $13.7 million (down 96.13% YoY), and the annual figure for FY2025 was $13.7 million, down 96.13%.
  • Cash from Financing Activities for Q4 2025 was $5.9 million at Syndax Pharmaceuticals, down from $6.3 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for SNDX hit a ceiling of $347.4 million in Q4 2024 and a floor of -$13.5 million in Q3 2022.
  • Median Cash from Financing Activities over the past 5 years was $2.3 million (2023), compared with a mean of $46.1 million.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 893.26% in 2022 and later surged 344.17% in 2023.
  • Syndax Pharmaceuticals' Cash from Financing Activities stood at $109.8 million in 2021, then soared by 48.94% to $163.5 million in 2022, then skyrocketed by 58.09% to $258.5 million in 2023, then surged by 34.41% to $347.4 million in 2024, then plummeted by 98.3% to $5.9 million in 2025.
  • The last three reported values for Cash from Financing Activities were $5.9 million (Q4 2025), $6.3 million (Q3 2025), and $551000.0 (Q2 2025) per Business Quant data.